Review
Oncology
Suvendu Purkait, Sanjeev Gupta, Sameer Bakhshi, Saumyaranjan Mallick
Summary: This article describes the clinicopathological features of three cases of BPDCN, including two with classical immunophenotype and one with an uncommon immunophenotype.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
(2022)
Article
Medical Laboratory Technology
Xiaofang Zhang, Yiping Wu, Chen Li, Keming Shen, Ruimin Li
Summary: The aim of this study was to investigate the clinical characteristics and diagnosis of acute myeloid leukemia with CD56- blastic plasmacytoid dendritic cell neoplasm. Three cases of elderly men with acute myeloid leukemia were analyzed retrospectively, and their bone marrow features suggested the diagnosis of acute myeloid leukemia with blastic plasmacytoid dendritic cell neoplasm. Flow cytometry and second generation sequencing were performed to detect abnormalities in myeloid cells and abnormal plasmacytoid dendritic cells, as well as gene mutations in RUNX1 and DNMT3A.
CLINICAL LABORATORY
(2023)
Review
Immunology
Ioana Plesca, Luise Mueller, Jan P. Boettcher, Hind Medyouf, Rebekka Wehner, Marc Schmitz
Summary: Dendritic cells (DCs) are crucial in orchestrating anti-tumor immunity, capable of producing proinflammatory cytokines, initiating T-cell responses, and exhibiting direct cytotoxicity against tumor cells. The functionality of DCs depends on intrinsic properties and the tumor microenvironment, with immunogenic DCs promoting tumor elimination and tolerogenic DCs fostering tumor progression.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2022)
Article
Dermatology
Brenna M. Aran, Juanita Duran, Darren Whittemore, Alejandro A. Gru
Summary: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive hematologic malignancy originating from plasmacytoid dendritic cells. Most patients initially present with cutaneous lesions. We report a case of TCF-4+ BPDCN with negative CD56 expression in an 85-year-old female with multiple skin nodules. BPDCN poses challenges in its diagnosis due to its unusual morphologic variants and phenotypes.
JOURNAL OF CUTANEOUS PATHOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Sabina Sanchez Hernandez, Martin Roelsgaard Jakobsen, Rasmus O. Bak
Summary: Plasmacytoid dendritic cells (pDCs) have multifaceted roles in immune responses, playing a crucial part in antiviral and antitumor immune activities. The therapeutic approach of utilizing pDCs to enhance tumor-specific immune responses has shown promising effects in clinical trials.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Xavier Roussel, Francine Garnache Ottou, Florian Renosi
Summary: Plasmacytoid dendritic cells (pDC) are the main type I interferon-producing cells in humans and are capable of regulating innate and adaptive immune responses. Tumor infiltration by pDC is well-documented in various cancers and is associated with unfavorable clinical outcomes. While Blastic Plasmacytoid Dendritic Cells Neoplasm (BPDCN) is a well-described aggressive leukemia derived from pDCs, the understanding of tumor infiltration by mature pDCs in Myeloid Neoplasms (MN) is limited. This review aims to provide a comprehensive overview of pDC biology in MN, emphasizing the need for further research into pDC oncogenesis and immune responses for better therapeutic strategies.
Article
Immunology
Tae Jin Yun, Suzu Igarashi, Haoquan Zhao, Oriana A. Perez, Marcus R. Pereira, Emmanuel Zorn, Yufeng Shen, Felicia Goodrum, Adeeb Rahman, Peter A. Sims, Donna L. Farber, Boris Reizis
Summary: Plasmacytoid dendritic cells (pDCs) can recognize live infected cells and produce a unique antiviral immune response, including high amounts of interferons, prolonged and efficient responses to CMV-infected cells, and activation of natural killer cells. Patients with CMV viremia show activated pDCs and increased circulating IFN-I and IFN-III.
SCIENCE IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Meiling Zheng, Zhi Hu, Xiaole Mei, Lianlian Ouyang, Yang Song, Wenhui Zhou, Yi Kong, Ruifang Wu, Shijia Rao, Hai Long, Wei Shi, Hui Jing, Shuang Lu, Haijing Wu, Sujie Jia, Qianjin Lu, Ming Zhao
Summary: This study compares the differences between cutaneous lesions from DLE and SLE patients and healthy controls using single-cell RNA sequencing data. The findings reveal differential immune cell recruitment, cell type, and gene expression, highlighting potential therapeutic targets for lupus erythematosus.
NATURE COMMUNICATIONS
(2022)
Article
Microbiology
Marilena P. Etna, Aurora Signorazzi, Daniela Ricci, Martina Severa, Fabiana Rizzo, Elena Giacomini, Andrea Gaggioli, Isabelle Bekeredjian-Ding, Anke Huckriede, Eliana M. Coccia
Summary: The study showed that inactivated TBEV (I-TBEV) induced differentiation of a sub-population of plasmacytoid dendritic cells (pDC) specialized in type I interferon production in human PBMC. This was critical for B cell differentiation to plasmablasts, highlighting the importance of preserving key viral molecules during vaccine manufacturing process.
Review
Cell Biology
Meng Feng, Shuping Zhou, Yong Yu, Qinghong Su, Xiaofan Li, Wei Lin
Summary: Dendritic cells (DCs) are a class of antigen-presenting cells with crucial roles in immune activation and tolerance. Understanding the migration mechanisms and regulatory factors of different DC subgroups provides new insights for disease treatment, such as infection, tumors, and vaccine preparation. Various factors, including chemokines, membrane molecules, and microenvironments, influence DC migration and immunological functions.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Pathology
Luisa Lorenzi, Silvia Lonardi, Donatella Vairo, Andrea Bernardelli, Michela Tomaselli, Mattia Bugatti, Sara Licini, Mariachiara Arisi, Lorenzo Cerroni, Alessandra Tucci, William Vermi, Silvia Clara Giliani, Fabio Facchetti
Summary: This study identifies EC as a novel pDC marker of diagnostic relevance in BPDCN. The results suggest a scenario where malignant pDCs promote the blunting of IFN-I signaling through EC-driven signaling, leading to a poorly immunogenic tumor microenvironment.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2021)
Article
Oncology
Jiaying Zheng, Lingxiao Wang, Shunyi Zhao, Wenjing Zhang, Yuzhou Chang, Dale B. Bosco, Tao Huang, Aastha Dheer, Shan Gao, Shengze Xu, Katayoun Ayasoufi, Rawan Al-Kharboosh, Fangfang Qi, Manling Xie, Aaron J. Johnson, Haidong Dong, Alfredo Quinones-Hinojosa, Long-Jun Wu
Summary: The study revealed significantly elevated levels of TREM2 expression in brain tumors compared to other types of tumors in patients, predominantly localized in tumor-associated myeloid cells. Surprisingly, TREM2 deficiency did not confer a beneficial effect in preclinical glioma models, instead accelerating glioma progression by impairing the phagocytosis of tumor cells and reducing MHCII expression, leading to decreased presence of CD4(+) T cells within the tumor hemispheres.
Article
Oncology
Huiguo Chen, Jianfeng Tan, Xiaojun Li, Hui Li, Weibin Wu, Yonghui Wu, Jian Zhang, Lijia Gu
Summary: The study demonstrated that a combined vaccine of myeloid dendritic cells and plasmacytoid dendritic cells loaded with heat-treated cancer cell lysates can enhance T lymphocyte proliferation and increase CTL-mediated cytotoxicity against lung cancer cells, leading to significant inhibition of tumor growth.
Article
Immunology
Binhui Zhou, Wenyi Yang, Wushan Li, Le He, Liaoxun Lu, Lichen Zhang, Zhuangzhuang Liu, Ying Wang, Tianzhu Chao, Rong Huang, Yanrong Gu, Tingting Jia, Qiaoli Liu, Shuanghua Tian, Philippe Pierre, Takahiro Maeda, Yinming Liang, Eryan Kong
Summary: Zdhhc2 plays a crucial role in controlling inflammatory response in psoriasis by regulating interferon-alpha production, and its deficiency leads to reduced inflammation and pDC activation in murine skin. This study sheds light on the potential of targeting Zdhhc2 as a therapeutic approach for inflammation.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Leilei Yang, Songya Li, Liuhui Chen, Yi Zhang
Summary: This article provides a comprehensive overview of the interactions between plasmacytoid dendritic cells (pDCs) and the tumor microenvironment (TME). The crosstalk between pDCs and other cell types, biochemical factors, and microorganisms plays a significant role in tumor development, making pDCs an intriguing target for therapeutic intervention. In-depth understanding of pDC crosstalk in the TME should facilitate the development of novel therapeutic methods.
CANCER BIOLOGY & MEDICINE
(2023)
